News | November 09, 2025
Poly Medicure posts Q2 FY26 consolidated net profit at Rs. 91.83 Cr
Poly Medicure has reported total income of Rs. 477.82 crore during the period ended September 30, 2025
Poly Medicure has reported total income of Rs. 477.82 crore during the period ended September 30, 2025
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Piramal Pharma has reported total income of Rs. 2,109.32 crore during the period ended September 30, 2025
Solara Active Pharma Sciences has reported total income of Rs. 314.03 crore during the period ended September 30, 2025
Caplin Point Laboratories has reported total income of Rs. 564.41 crore during the period ended September 30, 2025
SMS Pharmaceuticals has reported total income of Rs. 243.86 crore during the period ended September 30, 2025
Sun Pharmaceutical Industries has reported total income of Rs. 14,948.23 crore during the period ended September 30, 2025
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets
A bio-analytical Remote Regulatory Assessment was also conducted from October 30 to November 7, 2025, and concluded with no observations
Subscribe To Our Newsletter & Stay Updated
